arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

VERU INC.

VERU
$2.31 ▲ +0.02 (+0.65%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

VERU INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $53.2M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -16.4%
FCF / Share $-0.39
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-5.33M
↑ +40.4%
Operating Margin Operating profit as % of sales
-276.7%
↓ -15.7%
FCF / Share Free cash flow per share
$-0.39
↓ -27.3%
Long-Term Debt Long-term obligations
$1.70M
↑ +229.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
6
Financial Health
15
Cash Quality
76

Dividend History

Dividend / share · sourced from SEC filings
$0.21 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters